Andrew Moreo currently serves as the Head of Process Development, Plasmid, and Viral Vector Core Facilities at Andelyn Biosciences, where he leads a diverse organization of interdisciplinary scientists specializing in process development of new vector production platforms, as well as offering solutions to clients for accelerating gene therapy products to the patients who need them. Andrew has a B.S. in biology from Purdue University and two decades of experience in genetic and molecular research, with the last 15 years at Nationwide Children's Hospital and Andelyn focusing on AAV production and development.